A multicenter phase I study of CRS-207 in combination with pembrolizumab for the treatment of patients with metastatic gastric cancer who have failed at least two prior therapies

Trial Profile

A multicenter phase I study of CRS-207 in combination with pembrolizumab for the treatment of patients with metastatic gastric cancer who have failed at least two prior therapies

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs CRS 207 (Primary) ; Pembrolizumab
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2017 Status changed from planning to withdrawn prior to enrolment, as reported in an Aduro BioTech media release.
    • 13 Jan 2017 New trial record
    • 09 Jan 2017 According to an Aduro BioTech media release, the company plans to initiate this study in the first half of the year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top